Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Active, not recruiting
GlaxoSmithKline
Phase 1/Phase 2
2013-07-19
This phase I/II trial studies the side effects and the best dose of uprosertib when given
together with dabrafenib and trametinib and to see how well they work in treating patients
with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with
dabrafenib and trametinib may be a better treatment for cancer.
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Active, not recruiting
Novartis Pharmaceuticals
Phase 1/Phase 2
2013-07-19
This phase I/II trial studies the side effects and the best dose of uprosertib when given
together with dabrafenib and trametinib and to see how well they work in treating patients
with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with
dabrafenib and trametinib may be a better treatment for cancer.
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Active, not recruiting
National Cancer Institute (NCI)
Phase 1/Phase 2
2013-07-19
This phase I/II trial studies the side effects and the best dose of uprosertib when given
together with dabrafenib and trametinib and to see how well they work in treating patients
with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with
dabrafenib and trametinib may be a better treatment for cancer.
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Active, not recruiting
National Cancer Institute (NCI)
Phase 1
2013-08-29
This phase I trial studies the side effects and best dose of lapatinib when given together
with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery
and has not responded to previous treatment (refractory). Dabrafenib and lapatinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
